Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(Rac)-Lanicemine ((Rac)-AZD6765) 是 Lanicemine 的外消旋体。Lanicemine (AZD6765) 是一种低捕获的NMDA 受体拮抗剂,Ki 为 0.56-2.1 μM;在CHO 和非洲爪蟾卵母细胞中,IC50分别为 4-7 μM 和 6.4 μM。Lanicemine 具有抗抑郁作用。
产品描述 | (Rac)-Lanicemine ((Rac)-AZD6765) is the racemate of Lanicemine. Lanicemine (AZD6765) is a low-trapping NMDA channel blocker with Ki of 0.56-2.1 μM for NMDA receptor; IC 50 s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively. Lanicemine shows antidepressant effects [1]. |
体内活性 | Lanicemine produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects [1]. Lanicemine (3, 10 or 30 mg/kg; intraperitoneal) not only engages brain circuits involved in the generation of gamma- electroencephalography (EEG), but also affects these networks without the broader systems-level disruptions typical of ketamine [1]. Animal Model: Male Sprague-Dawley rats [1] Dosage: 3, 10 or 30 mg/kg Administration: Intraperitoneal Result: Produced pronounced dose-dependent elevations in spontaneous gamma-band EEG, but only gamma changes for Ketamine were tightly coupled to increases in locomotor activity. |
分子量 | 198.26 |
分子式 | C13H14N2 |
CAS No. | 61890-25-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(Rac)-Lanicemine 61890-25-3 Inhibitor inhibitor inhibit